Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/31/2014
Pfizer Investigational Site
mi
from
Federal Way, WA
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/31/2014
Pfizer Investigational Site
mi
from
Federal Way, WA
Click here to add this to my saved trials
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/31/2014
Pfizer Investigational Site
mi
from
Gig Harbor, WA
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/31/2014
Pfizer Investigational Site
mi
from
Gig Harbor, WA
Click here to add this to my saved trials
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/31/2014
Pfizer Investigational Site
mi
from
Lakewood, WA
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/31/2014
Pfizer Investigational Site
mi
from
Lakewood, WA
Click here to add this to my saved trials
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/31/2014
Pfizer Investigational Site
mi
from
Puyallup, WA
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/31/2014
Pfizer Investigational Site
mi
from
Puyallup, WA
Click here to add this to my saved trials
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/31/2014
Pfizer Investigational Site
mi
from
Tacoma, WA
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/31/2014
Pfizer Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/31/2014
Pfizer Investigational Site
mi
from
Gent,
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/31/2014
Pfizer Investigational Site
mi
from
Gent,
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of California at San Diego Moores Cancer Center
mi
from
San Diego, CA
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of California at San Diego Moores Cancer Center
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of Colorado Hospital
mi
from
Aurora, CO
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Yale University
mi
from
New Haven, CT
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of Chicago Medical Center
mi
from
Chicago, IL
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Mass General Hospital (MGH)
mi
from
Boston, MA
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Mass General Hospital (MGH)
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/16/2014
City of Hope National Medical Center
mi
from
Duarte, CA
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/16/2014
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/16/2014
Washington University School Of Medicine-Siteman Cancer Ctr Div. of Medical Oncology
mi
from
St. Louis, MO
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/16/2014
Washington University School Of Medicine-Siteman Cancer Ctr Div. of Medical Oncology
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/16/2014
Hackensack University Medical Center Hackensack (SC)
mi
from
Hackensack, NJ
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/16/2014
Hackensack University Medical Center Hackensack (SC)
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/16/2014
Memorial Sloan Kettering Cancer Center MSK 2
mi
from
New York, NY
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/16/2014
Memorial Sloan Kettering Cancer Center MSK 2
mi
from
New York, NY
Click here to add this to my saved trials
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/16/2014
Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State
mi
from
Columbus, OH
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/16/2014
Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/16/2014
University of Texas/MD Anderson Cancer Center SC Location
mi
from
Houston, TX
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/16/2014
University of Texas/MD Anderson Cancer Center SC Location
mi
from
Houston, TX
Click here to add this to my saved trials
The Cellularity Yield of Three Different 22-gauge Endoscopic Ultrasound Fine Needle Aspiration Needles
Status: Enrolling
Updated:  5/5/2014
Texas Tech University Health Sciences Center at El Paso
mi
from
El Paso, TX
The Cellularity Yield of Three Different 22-gauge Endoscopic Ultrasound Fine Needle Aspiration Needles
Status: Enrolling
Updated: 5/5/2014
Texas Tech University Health Sciences Center at El Paso
mi
from
El Paso, TX
Click here to add this to my saved trials
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  5/21/2014
Clinical Research Facility
mi
from
Detroit, MI
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 5/21/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  5/21/2014
Clinical Research Facility
mi
from
New Brunswick, NJ
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 5/21/2014
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  5/21/2014
Clinical Research Facility
mi
from
Dallas, TX
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 5/21/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Status: Enrolling
Updated:  6/5/2014
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Status: Enrolling
Updated: 6/5/2014
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Status: Enrolling
Updated:  6/5/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Status: Enrolling
Updated: 6/5/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Status: Enrolling
Updated:  6/5/2014
Hackensack University Medical Center
mi
from
Hackensack, NJ
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Status: Enrolling
Updated: 6/5/2014
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Status: Enrolling
Updated:  6/5/2014
Fred Hutchinson Cancer Research Center/University of Washington Medical Center
mi
from
Seattle, WA
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Status: Enrolling
Updated: 6/5/2014
Fred Hutchinson Cancer Research Center/University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Status: Enrolling
Updated:  6/5/2014
West Virginia University Mary Babb Randolf Cancer Center
mi
from
Morgantown, WV
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Status: Enrolling
Updated: 6/5/2014
West Virginia University Mary Babb Randolf Cancer Center
mi
from
Morgantown, WV
Click here to add this to my saved trials
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO(tm) Microdosing System
Status: Enrolling
Updated:  7/15/2014
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO(tm) Microdosing System
Status: Enrolling
Updated: 7/15/2014
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma
Status: Enrolling
Updated:  7/17/2014
Univ of Pennsylvania
mi
from
Philadelphia, PA
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma
Status: Enrolling
Updated: 7/17/2014
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated:  9/3/2014
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated: 9/3/2014
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated:  9/3/2014
Aurora St.Luke's Medical Center
mi
from
Milwaukee, WI
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial
Status: Enrolling
Updated: 9/3/2014
Aurora St.Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
Phase 1/2 Study of AMG 531 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Patients With Aggressive Non-Hodgkin's Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-C/MTX
Status: Enrolling
Updated:  9/4/2014
UT MD Anderson Cancer Center
mi
from
Houston, TX
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
Phase 1/2 Study of AMG 531 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Patients With Aggressive Non-Hodgkin's Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-C/MTX
Status: Enrolling
Updated: 9/4/2014
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Status: Enrolling
Updated:  10/9/2014
TG Therapeutics Investigational Trial Site
mi
from
Huntsville, AL
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Status: Enrolling
Updated: 10/9/2014
TG Therapeutics Investigational Trial Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Status: Enrolling
Updated:  10/9/2014
TG Therapeutics Investigational Trial Site
mi
from
Bethesda, MD
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Status: Enrolling
Updated: 10/9/2014
TG Therapeutics Investigational Trial Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 15
mi
from
Fountain Valley, CA
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 15
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site
mi
from
Los Angeles, CA
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 10269
mi
from
Orlando, FL
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 10269
mi
from
Orlando, FL
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 600
mi
from
Lafayette, IN
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 600
mi
from
Lafayette, IN
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 10158
mi
from
Bethesda, MD
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 10158
mi
from
Bethesda, MD
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 14670
mi
from
Hackensack, NJ
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 14670
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 10439
mi
from
Buffalo, NY
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 10439
mi
from
Buffalo, NY
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 43
mi
from
Gettysburg, PA
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 43
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 33
mi
from
Bryan, TX
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 33
mi
from
Bryan, TX
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 41
mi
from
Grapevine, TX
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 41
mi
from
Grapevine, TX
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 23
mi
from
Lynchburg, VA
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 23
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/28/2014
Teva Investigational Site 6
mi
from
Ottawa,
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/28/2014
Teva Investigational Site 6
mi
from
Ottawa,
Click here to add this to my saved trials
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Status: Enrolling
Updated:  11/13/2014
Froedtert Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Status: Enrolling
Updated: 11/13/2014
Froedtert Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Comparing the Efficacy of Endoscopic FNA vs FNB in Diagnosing Solid Gastrointestinal Lesions
Comparing the Overall Efficacy of Endoscopic Ultrasound Fine Needle Aspiration Versus Fine Needle Biopsy in the Diagnosis of Solid Lesions: A Multicenter, Randomized Clinical Trial
Status: Enrolling
Updated:  11/18/2014
Stony Brook University Hospital
mi
from
Stony Brook, NY
Comparing the Efficacy of Endoscopic FNA vs FNB in Diagnosing Solid Gastrointestinal Lesions
Comparing the Overall Efficacy of Endoscopic Ultrasound Fine Needle Aspiration Versus Fine Needle Biopsy in the Diagnosis of Solid Lesions: A Multicenter, Randomized Clinical Trial
Status: Enrolling
Updated: 11/18/2014
Stony Brook University Hospital
mi
from
Stony Brook, NY
Click here to add this to my saved trials